VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting
https://www.globenewswire.com/news-release/20...eting.html
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a leader in next-generation New Approach Methodologies (NAMs) 3d human cellular models for preclinical safety and translational efficacy, today announced that its scientific team will present new translational safety data at the American College of Toxicology (ACT) 47th Annual Meeting, November 15–18, 2026 in San Antonio, Texas.
The presentations will feature data generated across large multi-compound benchmarks and emerging modalities, including small molecules and antibody-drug conjugates (ADCs), demonstrating how VivoSim’s 3D human primary tissue platforms inform clinical safety risk for customer compounds under non-animal testing frameworks. The data will highlight that VivoSim’s multiparametric approach, measuring multiple tissue outcomes rather than overt cell death alone, provides a more detailed picture and superior predictive power.
“We look forward to sharing our latest translational methodology with the global toxicological community at ACT,” said Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs. “As biopharma sponsors increasingly integrate human-relevant NAMs to de-risk complex pipelines early, establishing decision-oriented frameworks for DILI and gastrointestinal toxicity is essential. Our presentations highlight how human 3D tissue models move beyond simple direct cell toxicity to deliver clinically predictive risk stratification.”
Members of VivoSim’s executive and scientific leadership teams will be on-site throughout the conference to discuss platform integration and commercial partnerships.
https://www.globenewswire.com/news-release/20...eting.html
SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a leader in next-generation New Approach Methodologies (NAMs) 3d human cellular models for preclinical safety and translational efficacy, today announced that its scientific team will present new translational safety data at the American College of Toxicology (ACT) 47th Annual Meeting, November 15–18, 2026 in San Antonio, Texas.
The presentations will feature data generated across large multi-compound benchmarks and emerging modalities, including small molecules and antibody-drug conjugates (ADCs), demonstrating how VivoSim’s 3D human primary tissue platforms inform clinical safety risk for customer compounds under non-animal testing frameworks. The data will highlight that VivoSim’s multiparametric approach, measuring multiple tissue outcomes rather than overt cell death alone, provides a more detailed picture and superior predictive power.
“We look forward to sharing our latest translational methodology with the global toxicological community at ACT,” said Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs. “As biopharma sponsors increasingly integrate human-relevant NAMs to de-risk complex pipelines early, establishing decision-oriented frameworks for DILI and gastrointestinal toxicity is essential. Our presentations highlight how human 3D tissue models move beyond simple direct cell toxicity to deliver clinically predictive risk stratification.”
Members of VivoSim’s executive and scientific leadership teams will be on-site throughout the conference to discuss platform integration and commercial partnerships.
